The importance of drug scheduling and recovery phases in determining drug activity: improving etoposide efficacy in BCR-ABL-positive CML cells
- 31 December 2002
- journal article
- Published by Elsevier in European Journal Of Cancer
- Vol. 38 (6) , 842-850
- https://doi.org/10.1016/s0959-8049(02)00016-3
Abstract
No abstract availableKeywords
This publication has 24 references indexed in Scilit:
- Changes in Cyclins and Cyclin-Dependent Kinases Induced by DNA Damaging Agents in a Human Ovarian Cancer Cell Line Expressing Mutated or Wild-Type P53Experimental Cell Research, 1996
- The mechanisms of DNA topoisomerasesTrends in Biochemical Sciences, 1995
- Cdc2 regulatory factorsCurrent Opinion in Cell Biology, 1994
- p21 is a universal inhibitor of cyclin kinasesNature, 1993
- WAF1, a potential mediator of p53 tumor suppressionCell, 1993
- Interleukin 3 protects murine bone marrow cells from apoptosis induced by DNA damaging agents.The Journal of Experimental Medicine, 1992
- Universal control mechanism regulating onset of M-phaseNature, 1990
- In vitro cytotoxicity of VP 16 on primary tumor and metastasis of Lewis lung carcinomaEuropean Journal of Cancer and Clinical Oncology, 1982
- A New Consistent Chromosomal Abnormality in Chronic Myelogenous Leukaemia identified by Quinacrine Fluorescence and Giemsa StainingNature, 1973
- Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4Nature, 1970